



15 July, 2020  
JCR Pharmaceuticals Co., Ltd.

Translation

**Notice regarding Finalized Details of issuance of Stock Options  
as Stock-linked Compensation (Share Subscription Rights)**

With respect to the matter of issuance of stock options as stock-linked compensation, resolved in the Ordinary General Shareholder's Meeting held on June 24, 2020, JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, "the Company") announced that it has finalized the paid-in amount for the share subscription rights as described below.

1. Name of the share subscription rights  
JCR Pharmaceuticals Co., Ltd., the first share subscription rights in 2020
2. Paid-in amount for the share subscription rights  
The amount for one share subscription right shall be 998,600 yen (9,986 yen per share)  
The Company shall regard the monetary compensation equivalent to the paid-in amount to be paid to the recipients of the new share subscription rights, subject to the allotment of the share subscription rights (the amount calculated by multiplying the paid-in amount for the said new share subscription rights by the number of new share subscription rights allotted), and they shall obtain the share subscription rights by offsetting the said payment liabilities with their claims for compensation from the Company.
3. Total number of share subscription rights  
155 rights
4. Recipients of the share subscription rights, the number of recipients, and the number of share subscription rights to be allots

Directors (excluding outside directors) of the Company	5 persons	115 rights
President of an overseas subsidiary of the Company	1 person	5 rights
Corporate officers of the Company	4 persons	35 rights

(For your reference)

Date of resolution in the Board of Directors meeting regarding the submission of a proposal at the Ordinary General Shareholders' Meeting	May 12, 2020
Date of resolution in the Ordinary General Shareholder's Meeting	June 24, 2020

**[About JCR Pharmaceuticals]**

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives

JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

**[Cautionary Statement Regarding Forward-Looking Statements]**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

END

###